Loading
Zevor-cel is CARsgen's myeloma CAR-T, approved in China in 2024 for patients whose disease has come back after three or more treatments.
Approved by the NMPA in February 2024 for relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory drug, on the LUMMICAR STUDY 1 phase 1/2 trial run in China. CARsgen reported high response rates with deep remissions and mostly low-grade cytokine release syndrome; the full phase 2 report appeared in Experimental Hematology and Oncology in 2025. Commercialised in China with Huadong Medicine. CARsgen's second approval, satricabtagene autoleucel for Claudin 18.2-positive gastric cancer, followed in 2025.
Autologous T cells transduced with a fully human anti-BCMA CAR (4-1BB co-stimulation) developed by CARsgen from its Shanghai platform. Connects to BCMA.
1.Zevorcabtagene autoleucel slips into a pocket on BCMA.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2024 | Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
One trial page and one treatment page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this drug: (TITLE:"Zevorcabtagene autoleucel" OR ABSTRACT:"Zevorcabtagene autoleucel" OR TITLE:"Saikaize" OR ABSTRACT:"Saikaize" OR TITLE:"zevor-cel" OR ABSTRACT:"zevor-cel" OR TITLE:"CT053" OR ABSTRACT:"CT053") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zevorcabtagene autoleucel, not a curated reading list.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares CARsgen Therapeutics, CAR-T cell therapy and the tag china.
Shares CARsgen Therapeutics, CAR-T cell therapy and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.
Shares CAR-T cell therapy and the tag china.